Incyte - INCY Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.
View INCY analyst ratings or view top-rated stocks.

7 brokerages have issued 1-year price targets for Incyte's shares. Their INCY share price forecasts range from $63.00 to $98.00. On average, they expect the company's stock price to reach $78.75 in the next twelve months. This suggests that the stock has a possible downside of 8.4%.
View analysts price targets for INCY or view top-rated stocks among Wall Street analysts.

Incyte's stock was trading at $80.32 at the beginning of 2023. Since then, INCY shares have increased by 7.1% and is now trading at $86.01.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023.
View our INCY earnings forecast.

Incyte will be holding an earnings conference call on Tuesday, February 7th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-612-7415 with passcode "13735569".

Incyte Co. (NASDAQ:INCY) posted its earnings results on Tuesday, November, 1st. The biopharmaceutical company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.54 by $0.10. The biopharmaceutical company earned $823.30 million during the quarter, compared to analysts' expectations of $847 million. Incyte had a trailing twelve-month return on equity of 9.04% and a net margin of 26.30%.

22 employees have rated Incyte Chief Executive Officer Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (0.50%), ARK Investment Management LLC (0.43%), Country Trust Bank (0.21%), Allspring Global Investments Holdings LLC (0.20%), Grimes & Company Inc. (0.09%) and National Bank of Canada FI (0.05%). Insiders that own company stock include Barry P Flannelly, Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Thomas Tray, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing.
View institutional ownership trends.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INCY stock can currently be purchased for approximately $86.01.

Incyte (NASDAQ:INCY) has a market capitalization of $19.14 billion and generates $2.99 billion in revenue each year. The biopharmaceutical company earns $948.58 million in net income (profit) each year or $3.93 on an earnings per share basis.

The company employs 2,094 workers across the globe.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The official website for the company is www.incyte.com. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at mbooth@incyte.com, or via fax at 302-425-2750.